Nigrofrontal dopaminergic function as assessed by18F-dopa pet

M. Otsuka, Y. Ichiya, Y. Kuwabara, Masayuki Sasaki, T. Yoshida, T. Fukumura, K. Masuda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The existence of the nigrofrontal dopaminergic pathway has been demonstrated in neuroanatomical studies. We evaluated the presynaptic nigrofrontal dopaminergic function using,18F-dopa (FD) positron emission tomography (PET). TTie multiple time PET data in the frontal cortex from 20 to 70 min postinjection for FD were evaluated by Patlak analysis using the cerebellar time-activity curve as an input function. The frontal FD uptake rate constants could not be determined in 5 of 12 normal volunteers because of large deviations in the plots. There were no significant differences between the subjects among whom the frontal FD uptake rate constants could or could not be determined regarding the amount of FD injected, the frontal 18F counts, or whether or not they were pretreated with carbidopa. The uptake constants were determined in 9 of 12 patients with parkinsonian syndrome. While the mean (± S.D.) uptake constants in patients with Parkinson's disease (2.89 ± 0.06 × 10-3; n = 4) and in patients with progressive supranuclear palsy (2.81 ± 0.10 × 10-3; « = 3) were not significantly different from those in the normal volunteers (2.93 ± 0.14 × 10-3), those in two patients with corticobasal degeneration (2.42 and 2.46, respectively) decreased in comparison to the control values. Differences in the nigrofrontal presynaptic dopaminergic function as assessed by FD-PET may explain the different pathogenesis and also help to differentiate between corticobasal degeneration and other parkinsonian syndromes, such as Parkinson's disease and progressive supranuclear palsy.

Original languageEnglish
Pages (from-to)1021-1025
Number of pages5
JournalNuclear Medicine Communications
Volume16
Issue number12
DOIs
Publication statusPublished - Jan 1 1995

Fingerprint

Dihydroxyphenylalanine
Pets
Positron-Emission Tomography
Progressive Supranuclear Palsy
Parkinsonian Disorders
Parkinson Disease
Healthy Volunteers
Carbidopa
Frontal Lobe

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Otsuka, M., Ichiya, Y., Kuwabara, Y., Sasaki, M., Yoshida, T., Fukumura, T., & Masuda, K. (1995). Nigrofrontal dopaminergic function as assessed by18F-dopa pet. Nuclear Medicine Communications, 16(12), 1021-1025. https://doi.org/10.1097/00006231-199512000-00006

Nigrofrontal dopaminergic function as assessed by18F-dopa pet. / Otsuka, M.; Ichiya, Y.; Kuwabara, Y.; Sasaki, Masayuki; Yoshida, T.; Fukumura, T.; Masuda, K.

In: Nuclear Medicine Communications, Vol. 16, No. 12, 01.01.1995, p. 1021-1025.

Research output: Contribution to journalArticle

Otsuka, M, Ichiya, Y, Kuwabara, Y, Sasaki, M, Yoshida, T, Fukumura, T & Masuda, K 1995, 'Nigrofrontal dopaminergic function as assessed by18F-dopa pet', Nuclear Medicine Communications, vol. 16, no. 12, pp. 1021-1025. https://doi.org/10.1097/00006231-199512000-00006
Otsuka, M. ; Ichiya, Y. ; Kuwabara, Y. ; Sasaki, Masayuki ; Yoshida, T. ; Fukumura, T. ; Masuda, K. / Nigrofrontal dopaminergic function as assessed by18F-dopa pet. In: Nuclear Medicine Communications. 1995 ; Vol. 16, No. 12. pp. 1021-1025.
@article{37e50ebb524b40c3a8c681094178f4df,
title = "Nigrofrontal dopaminergic function as assessed by18F-dopa pet",
abstract = "The existence of the nigrofrontal dopaminergic pathway has been demonstrated in neuroanatomical studies. We evaluated the presynaptic nigrofrontal dopaminergic function using,18F-dopa (FD) positron emission tomography (PET). TTie multiple time PET data in the frontal cortex from 20 to 70 min postinjection for FD were evaluated by Patlak analysis using the cerebellar time-activity curve as an input function. The frontal FD uptake rate constants could not be determined in 5 of 12 normal volunteers because of large deviations in the plots. There were no significant differences between the subjects among whom the frontal FD uptake rate constants could or could not be determined regarding the amount of FD injected, the frontal 18F counts, or whether or not they were pretreated with carbidopa. The uptake constants were determined in 9 of 12 patients with parkinsonian syndrome. While the mean (± S.D.) uptake constants in patients with Parkinson's disease (2.89 ± 0.06 × 10-3; n = 4) and in patients with progressive supranuclear palsy (2.81 ± 0.10 × 10-3; « = 3) were not significantly different from those in the normal volunteers (2.93 ± 0.14 × 10-3), those in two patients with corticobasal degeneration (2.42 and 2.46, respectively) decreased in comparison to the control values. Differences in the nigrofrontal presynaptic dopaminergic function as assessed by FD-PET may explain the different pathogenesis and also help to differentiate between corticobasal degeneration and other parkinsonian syndromes, such as Parkinson's disease and progressive supranuclear palsy.",
author = "M. Otsuka and Y. Ichiya and Y. Kuwabara and Masayuki Sasaki and T. Yoshida and T. Fukumura and K. Masuda",
year = "1995",
month = "1",
day = "1",
doi = "10.1097/00006231-199512000-00006",
language = "English",
volume = "16",
pages = "1021--1025",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Nigrofrontal dopaminergic function as assessed by18F-dopa pet

AU - Otsuka, M.

AU - Ichiya, Y.

AU - Kuwabara, Y.

AU - Sasaki, Masayuki

AU - Yoshida, T.

AU - Fukumura, T.

AU - Masuda, K.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The existence of the nigrofrontal dopaminergic pathway has been demonstrated in neuroanatomical studies. We evaluated the presynaptic nigrofrontal dopaminergic function using,18F-dopa (FD) positron emission tomography (PET). TTie multiple time PET data in the frontal cortex from 20 to 70 min postinjection for FD were evaluated by Patlak analysis using the cerebellar time-activity curve as an input function. The frontal FD uptake rate constants could not be determined in 5 of 12 normal volunteers because of large deviations in the plots. There were no significant differences between the subjects among whom the frontal FD uptake rate constants could or could not be determined regarding the amount of FD injected, the frontal 18F counts, or whether or not they were pretreated with carbidopa. The uptake constants were determined in 9 of 12 patients with parkinsonian syndrome. While the mean (± S.D.) uptake constants in patients with Parkinson's disease (2.89 ± 0.06 × 10-3; n = 4) and in patients with progressive supranuclear palsy (2.81 ± 0.10 × 10-3; « = 3) were not significantly different from those in the normal volunteers (2.93 ± 0.14 × 10-3), those in two patients with corticobasal degeneration (2.42 and 2.46, respectively) decreased in comparison to the control values. Differences in the nigrofrontal presynaptic dopaminergic function as assessed by FD-PET may explain the different pathogenesis and also help to differentiate between corticobasal degeneration and other parkinsonian syndromes, such as Parkinson's disease and progressive supranuclear palsy.

AB - The existence of the nigrofrontal dopaminergic pathway has been demonstrated in neuroanatomical studies. We evaluated the presynaptic nigrofrontal dopaminergic function using,18F-dopa (FD) positron emission tomography (PET). TTie multiple time PET data in the frontal cortex from 20 to 70 min postinjection for FD were evaluated by Patlak analysis using the cerebellar time-activity curve as an input function. The frontal FD uptake rate constants could not be determined in 5 of 12 normal volunteers because of large deviations in the plots. There were no significant differences between the subjects among whom the frontal FD uptake rate constants could or could not be determined regarding the amount of FD injected, the frontal 18F counts, or whether or not they were pretreated with carbidopa. The uptake constants were determined in 9 of 12 patients with parkinsonian syndrome. While the mean (± S.D.) uptake constants in patients with Parkinson's disease (2.89 ± 0.06 × 10-3; n = 4) and in patients with progressive supranuclear palsy (2.81 ± 0.10 × 10-3; « = 3) were not significantly different from those in the normal volunteers (2.93 ± 0.14 × 10-3), those in two patients with corticobasal degeneration (2.42 and 2.46, respectively) decreased in comparison to the control values. Differences in the nigrofrontal presynaptic dopaminergic function as assessed by FD-PET may explain the different pathogenesis and also help to differentiate between corticobasal degeneration and other parkinsonian syndromes, such as Parkinson's disease and progressive supranuclear palsy.

UR - http://www.scopus.com/inward/record.url?scp=0029566954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029566954&partnerID=8YFLogxK

U2 - 10.1097/00006231-199512000-00006

DO - 10.1097/00006231-199512000-00006

M3 - Article

C2 - 8719983

AN - SCOPUS:0029566954

VL - 16

SP - 1021

EP - 1025

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 12

ER -